{"id":120806,"date":"2025-05-21T21:22:08","date_gmt":"2025-05-21T21:22:08","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/120806\/"},"modified":"2025-05-21T21:22:08","modified_gmt":"2025-05-21T21:22:08","slug":"the-glp-1-drug-landscape-changes-on-thursday","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/120806\/","title":{"rendered":"The GLP-1 Drug Landscape Changes on Thursday"},"content":{"rendered":"<p class=\"storyParagraph\">&#13;<br \/>\n                                        The GLP-1 drug landscape is about to change. Starting Thursday, off-brand versions of semaglutide will no longer be permitted to be sold\u2014creating a possible problem for the Americans who&#8217;ve come to rely on the generally cheaper option. The FDA <a href=\"https:\/\/www.newser.com\/story\/364751\/fda-change-on-ozempic-to-shake-up-the-market.html\" target=\"_blank\" rel=\"noopener\">in February announced<\/a> that the shortage of the active ingredient in Ozempic and Wegovy, semaglutide, that had persisted since 2022 had been resolved; that meant the ability of compounding pharmacies to step in and help ease the gap created by the lack of the brand-name products was also coming to an end.&#13;\n                                    <\/p>\n<p class=\"storyParagraph\">&#13;<br \/>\n                                        <a href=\"https:\/\/www.cnn.com\/2025\/05\/21\/health\/fda-compounded-semaglutide-tirzepatide-crackdown\" target=\"_blank\" rel=\"noopener\">CNN<\/a> reports the grace period for manufacturers to stop producing and selling compounded tirzepatide (sold under the brand names Zepbound and Mounjaro) wrapped up in March; now compounded semaglutide&#8217;s period is at its end. As for what that means for the patients who use it, CNN offers the story of Olympia Pharmaceuticals and Michelle Pierce. The company&#8217;s compounded GLP-1 drugs reach more than 70,000 people each week, Pierce among them.&#13;\n                                    <\/p>\n<p class=\"storyParagraph\">&#13;<br \/>\n                                        The 25-year-old Texan said insurance refused to cover GLP-1 medications multiple times. She turned to Olympia&#8217;s compounded version and says it has been &#8220;life-changing&#8221;; she credits it with helping her avoid back surgery and get her blood sugar A1c level to an all-time low. Now, she says she only has one path forward: Stop taking it. &#8220;I absolutely cannot afford to completely pay out of pocket,&#8221; she said. Still, the <a href=\"https:\/\/www.wsj.com\/health\/pharma\/ozempic-knockoffs-survive-crackdown-thanks-to-loophole-7c5b02d7\" target=\"_blank\" rel=\"noopener\">Wall Street Journal<\/a> notes the door might not be totally shutting. Some compounding pharmacies and telehealth companies are attempting a work-around by making and selling drugs that are a hair different than the FDA-approved versions, such as by adding B vitamins and amino acids or changing the form from an injectable to under-the-tongue drops or pills.  (More <a href=\"https:\/\/www.newser.com\/tag\/77643\/1\/semaglutide.html\" target=\"_blank\" rel=\"noopener\">semaglutide<\/a> stories.)&#13;\n                                    <\/p>\n","protected":false},"excerpt":{"rendered":"&#13; The GLP-1 drug landscape is about to change. Starting Thursday, off-brand versions of semaglutide will no longer&hellip;\n","protected":false},"author":2,"featured_media":120807,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[53892,16231,105,4326,370,32969,16,15,10891,734],"class_list":{"0":"post-120806","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-compounding-pharmacies","9":"tag-glp-1","10":"tag-health","11":"tag-medication","12":"tag-ozempic","13":"tag-semaglutide","14":"tag-uk","15":"tag-united-kingdom","16":"tag-wegovy","17":"tag-weight-loss"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114547926234850408","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/120806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=120806"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/120806\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/120807"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=120806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=120806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=120806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}